

Enhanced Analysis of Host Cell Proteins Using the Agilent 6545XT AdvanceBio LC/Q-TOF

Linfeng Wu, Ph.D.
LC/MS Application Scientist
ASMS 2017



Introduction

Residual Host Cell Protein (HCP) are process impurities remained in a purified drug product

- HCPs can influence product stability and cause immune response in patients
- FDA requires that HCP contaminants in the final product are measured and reported
- ELISA is still a widely accepted method for HCP quantification
 - Strengths:
 - Very sensitive (ppb detection limits)
 - High level of reproducibility
 - High-throughput (plate format, automation)
 - Challenges:
 - Lack of specificity, no identification of individual HCPs
 - Lack of coverage for non-immunoreactive HCPs
 - Quantitation is based on a cohort of HCPs

LC/MS as a Solution for Host Cell Protein Analysis




Advantages:

- Identify individual protein including immunogenic HCPs
- Improve early purification process development
- Doesn't require protein specific antibodies
- High analytical sensitivity (low ppm)
- Provide both qualitative and quantitative information

Challenge for LC/MS Analysis of HCPs

- Low abundant HCP peptides co-elute with very intense “product” mAb peptides
- Need broad dynamic range and better separation, and 2D-LC is often used



Host Cell Protein Analysis Workflow




Protein Reduction,
Alkylation and Digestion


6545XT AdvanceBio
LC/Q-TOF Using
IterativeMS/MS

Match MS/MS Spectra
to Database

Different MS/MS Scan Types




Automated IterativeMS/MS Acquisition





LC/MS
Run 1



LC/MS
Run 2



Additional Runs ...

-  Precursors selected for MS/MS
-  Rolling excluded precursors

Experiment Design

- Spike-in UPS2 standards in purified CHO-cultured mAb to assess low-level HCP identification and quantification
 - Proteomics Dynamic Range Standard (UPS2) Commercial mix of 48 proteins at 6 concentrations, spanning 6 orders of magnitude, 8 proteins per concentration level
 - mAb without UPS2 spike was used as a negative control
- Sample preparation without off-line fractionation or desalting
- Standard-flow 60min 1D LC on an AdvanceBio Peptide Plus column (2.1x150 mm)
- Data-dependent acquisition (DDA)
- Data analysis
 - IterativeMS/MS vs. AutoMS/MS
 - HCP identification sensitivity
 - HCP label-free quantification precision
 - HCP quantification reproducibility

IterativeMS/MS Decision Engine Improves Protein Identification

IterativeMS/MS with 5 injections vs. autoMS/MS with 5 injections

| Protein name | Actual Protein Level (ppm) | Unique peptide # | | Spectra # | |
|---------------------------------------|----------------------------|------------------|------------|-----------------|------------|
| | | Iterative MS/MS | Auto MS/MS | Iterative MS/MS | Auto MS/MS |
| mAb heavy chain | 6.8E+05 | 589 | 491 | 5193 | 9738 |
| mAb light chain | 3.2E+05 | 261 | 208 | 2012 | 3925 |
| Serum albumin | 313.0 | 33 | 21 | 82 | 144 |
| Carbonic anhydrase 2 | 137.3 | 12 | 9 | 34 | 53 |
| Carbonic anhydrase 1 | 135.6 | 11 | 9 | 29 | 62 |
| Leptin | 76.2 | 6 | 3 | 14 | 26 |
| Hemoglobin subunit beta | 74.8 | 8 | 7 | 21 | 44 |
| Hemoglobin subunit alpha | 71.3 | 7 | 4 | 15 | 22 |
| Ubiquitin | 50 | 4 | 2 | 13 | 18 |
| Small ubiquitin-related modifier 1 | 18.3 | 6 | 0 | 9 | 0 |
| Peroxiredoxin 1 | 10.4 | 3 | 2 | 7 | 18 |
| Peptidyl-prolyl cis-trans isomerase A | 9.5 | 3 | 0 | 4 | 0 |
| Myoglobin | 8 | 0 | 3 | 0 | 11 |

Data analysis using Byonic[®] with 1%FDR:

- IterativeMS/MS -> more unique peptides
- IterativeMS/MS -> less redundant spectra

Comparison of Identified Protein Levels

-- five experiments with different loading amount, injection numbers and acquisition modes

| Protein name | Molecular weight (Da) | Actual Protein Level (ppm) | Unique peptide # | | | | |
|---|-----------------------|----------------------------|--------------------------------|--------------------------------|---------------------------|---------------------------|---------------------------|
| | | | IterativeMS/MS (24µg x 5 inj.) | IterativeMS/MS (32µg x 3 inj.) | AutoMS/MS (24µg x 5 inj.) | AutoMS/MS (24µg x 1 inj.) | AutoMS/MS (32µg x 1 inj.) |
| Serum albumin | 66,357 | 313.0 | 33 | 32 | 21 | 16 | 22 |
| Carbonic anhydrase 2 | 29,115 | 137.3 | 12 | 9 | 9 | 5 | 7 |
| Carbonic anhydrase 1 | 28,739 | 135.6 | 11 | 9 | 9 | 5 | 6 |
| Leptin | 16,158 | 76.2 | 6 | 4 | 3 | 2 | 3 |
| Hemoglobin subunit beta | 15,867 | 74.8 | 8 | 7 | 7 | 5 | 3 |
| Hemoglobin subunit alpha | 15,126 | 71.3 | 7 | 3 | 4 | 3 | 2 |
| Ubiquitin | 10,597 | 50.0 | 4 | 5 | 2 | 2 | 5 |
| Complement C5/C5a anaphylatoxin | 8,563 | 40.4 | 1 | 1 | 3 | 2 | 1 |
| Catalase | 59,625 | 28.1 | 0 | 3 | 8 | 3 | 0 |
| Small ubiquitin-related modifier 1 (SUMO-1) | 38,815 | 18.3 | 6 | 2 | 7 | 0 | 0 |
| NAD(P)H dehydrogenase [quinone] 1 | 30,736 | 14.5 | 0 | 2 | 0 | 0 | 2 |
| Peroxiredoxin 1 | 21,979 | 10.4 | 3 | 5 | 2 | 2 | 5 |
| Peptidyl-prolyl cis-trans isomerase A | 20,176 | 9.5 | 3 | 4 | 3 | 1 | 2 |
| Myoglobin | 17,053 | 8.0 | 1 | 1 | 3 | 0 | 0 |
| Cytochrome b5 | 16,022 | 7.6 | 0 | 0 | 0 | 0 | 0 |
| Pro-epidermal growth factor (EGF)/Epidermal growth factor | 6,353 | 3.0 | 0 | 0 | 0 | 0 | 0 |
| Histidyl-tRNA synthetase, cytoplasmic | 58,233 | 2.7 | 6 | 4 | 8 | 2 | 0 |
| Creatine kinase M-type | 43,101 | 2.0 | 0 | 0 | 0 | 0 | 0 |
| Ribosylidihyronicotinamide dehydrogenase | 25,821 | 1.2 | 0 | 0 | 0 | 0 | 0 |

Data analysis using Byonic[®] followed by Byologic[®] software

Comparison of Identified Protein Levels



-- five experiments with different loading amount, injection numbers and acquisition modes

| Protein name | Molecular weight (Da) | Actual Protein Level (ppm) | Unique peptide # | | | | |
|---|-----------------------|----------------------------|--------------------------------|--------------------------------|---------------------------|---------------------------|---------------------------|
| | | | IterativeMS/MS (24µg x 5 inj.) | IterativeMS/MS (32µg x 3 inj.) | AutoMS/MS (24µg x 5 inj.) | AutoMS/MS (24µg x 1 inj.) | AutoMS/MS (32µg x 1 inj.) |
| Serum albumin | 66,357 | 313.0 | 33 | 32 | 21 | 16 | 22 |
| Carbonic anhydrase 2 | 29,115 | 137.3 | 12 | 9 | 9 | 5 | 7 |
| Carbonic anhydrase 1 | 28,739 | 135.6 | 11 | 9 | 9 | 5 | 6 |
| Leptin | 16,158 | 76.2 | 6 | 4 | 3 | 2 | 3 |
| Hemoglobin subunit beta | 15,867 | 74.8 | 8 | 7 | 7 | 5 | 3 |
| Hemoglobin subunit alpha | 15,126 | 71.3 | 7 | 3 | 4 | 3 | 2 |
| Ubiquitin | 10,597 | 50.0 | 4 | 5 | 2 | 2 | 5 |
| Complement C5/C5a anaphylatoxin | 8,563 | 40.4 | 1 | 1 | 3 | 2 | 1 |
| Catalase | 59,625 | 28.1 | 0 | 3 | 8 | 3 | 0 |
| Small ubiquitin-related modifier 1 (SUMO-1) | 38,815 | 18.3 | 6 | 2 | 7 | 0 | 0 |
| NAD(P)H dehydrogenase [quinone] 1 | 30,736 | 14.5 | 0 | 2 | 0 | 0 | 2 |
| Peroxiredoxin 1 | 21,979 | 10.4 | 3 | 5 | 2 | 2 | 5 |
| Peptidyl-prolyl cis-trans isomerase A | 20,176 | 9.5 | 3 | 4 | 3 | 1 | 2 |
| Myoglobin | 17,053 | 8.0 | 1 | 1 | 3 | 0 | 0 |
| Cytochrome b5 | 16,022 | 7.6 | 0 | 0 | 0 | 0 | 0 |
| Pro-epidermal growth factor (EGF)/Epidermal growth factor | 6,353 | 3.0 | 0 | 0 | 0 | 0 | 0 |
| Histidyl-tRNA synthetase, cytoplasmic | 58,233 | 2.7 | 6 | 4 | 8 | 2 | 0 |
| Creatine kinase M-type | 43,101 | 2.0 | 0 | 0 | 0 | 0 | 0 |
| Ribosylidihyronicotinamide dehydrogenase | 25,821 | 1.2 | 0 | 0 | 0 | 0 | 0 |

- Triplicate injections with IterativeMS/MS allows identification of HCPs in single-digit ppm level
- Multiple unique peptides identified for HCP at 2.7 ppm


Excellent Precision for HCP Label-free Quantification

HCP levels were calculated based on one internal reference protein



- UPS2 protein levels were calculated based on Carbonic Anhydrase 1, and then plotted with their actual spike-in levels:
 - Excellent linearity was achieved by using either IterativeMS/MS ($R^2 = 0.9732$) or AutoMS/MS ($R^2=0.9383$) dataset

Broad Dynamic Range for Co-eluting Peptides




| Peptide | Precursor ion (m/z) | Mass error (ppm) | Intensity | Actual Protein Level (ppm) | Protein name |
|-------------|---------------------|------------------|-----------|----------------------------|-------------------------|
| ALELFR | 374.7208 | -1.1 | 6.76E+03 | 8 | Myoglobin |
| SAVTALWGK | 466.7659 | 4.8 | 1.36E+05 | 74.8 | Hemoglobin subunit beta |
| TIAQDYGVLK | 554.3049 | -1.8 | 1.51E+05 | 10.4 | Peroxiredoxin 1 |
| EPQVYTLPPSR | 643.844 | 1.0 | 1.38E+08 | 1.0E+06 | mAb |

- High loading capacity (32 µg on-column)
- Broad dynamic range for co-eluting peptides
 - peptide intensity > 4 orders
 - protein in weight > 5 orders

Excellent Chromatography Reproducibility

Overlay chromatograms of triplicate runs



| Peptide | Precursor ion (m/z) | Mass error (ppm) | Intensity | Intensity %RSD | Actual Protein Level (ppm) | Protein name |
|-------------|---------------------|------------------|-----------|----------------|----------------------------|-------------------------|
| ALELFR | 374.7208 | -1.1 | 6.76E+03 | 10.3% | 8 | Myoglobin |
| SAVTALWGK | 466.7659 | 4.8 | 1.36E+05 | 6.0% | 74.8 | Hemoglobin subunit beta |
| TIAQDYGVLK | 554.3049 | -1.8 | 1.51E+05 | 6.2% | 10.4 | Peroxiredoxin 1 |
| EPQVYTLPPSR | 643.844 | 1.0 | 1.38E+08 | 1.2% | 1.0E+06 | mAb |

Summary

- 1D LC/MS solution: no off-line fractionation or desalting
- Simple data processing with DDA data
- Automated IterativeMS/MS improves protein identification coverage
- Identification of low-level (< 10ppm) HCPs
- Simultaneous identification and quantification

Acknowledgements



Xinning Jiang

Te-Wei Chu

Alex Zhu

Jordy J. Hsiao



Eric Carlson